US FDA finds control lapses at Moderna manufacturing plant 

Health

Reuters exclusively reported that U.S. drug regulators in September found quality control lapses at Moderna’s (MRNA.O) main factory including with equipment used to manufacture drug substance for its COVID-19 vaccine. 

Market Impact

Moderna in September said it was in talks with its partners that fill vials and syringes with its COVID vaccine globally to downsize production and bring more manufacturing in-house as demand has waned. The vaccine maker said it expects additional capacity from its new mRNA manufacturing facilities in the UK, Canada and Australia when completed in 2025.

Article Tags

Topics of Interest: Health

Type: Reuters Best

Sectors: Government & Public ServicesPharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Source link

Leave a Comment